A second-look TUR in T1 transitional cell carcinoma: why?

Area of Science:

• Uro-oncology
• Surgical oncology
• Pathology

Background:

• Transitional cell cancer (T1) of the urinary bladder carries a high risk of progression after transurethral resection (TUR) alone.
• While intravesical immunotherapy can mitigate risks, long-term data show significant rates of bladder loss or death from recurrent tumors.
• Cystectomy is an alternative, but may be performed unnecessarily in some patients, leading to complications of urinary diversion.

Purpose of the Study:

• To evaluate the quality of transurethral resection (TUR) in T1 bladder cancer.
• To highlight the implications of residual tumor after TUR on treatment decisions.
• To recommend a standardized approach for managing T1 bladder cancer, including the potential role of a second TUR.

Main Methods:

• Review of current literature on transurethral resection (TUR) quality and outcomes in T1 bladder cancer.
• Analysis of findings from recent publications regarding residual tumor detection after initial TUR.
• Examination of retrospective studies supporting the clinical implications of TUR quality.

Main Results:

• A 'textbook' transurethral resection (TUR) with complete tumor clearance and adequate biopsies is not consistently achievable.
• Significant residual tumor is often left after TUR, leading to local recurrence or progression.
• A second TUR frequently detects residual tumors of similar or higher stage, impacting treatment strategies.

Conclusions:

• The quality of transurethral resection (TUR) is critical for managing T1 bladder cancer.
• A second TUR, performed 2-4 weeks after the initial procedure, is strongly recommended for future conservative treatment studies.
• Accurate staging and management of T1 bladder cancer require careful consideration of TUR quality and potential residual disease.